
Opinion|Videos|May 6, 2024
Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement





















